Jennifer Lue, MD

Dr. Jennifer Lue is an Assistant Professor at the Columbia University Medical Center and a member of the Center for Lymphoid Malignancies. Dr. Lue obtained her Bachelors of Arts in Biology with Honors from New York University, followed by her Medical Doctorate from the New York University School of Medicine.  Following her graduation from medical school, she conducted her residency in Internal Medicine at the New York University Medical Center and completed her Hematology-Oncology Fellowship at Columbia University Medical Center. 

Dr. Lue’s research interest focuses on the development of novel drug therapies in lymphomas, targeting epigenetic pathways underlying the pathogenesis of these diseases.  Her early work centered on EZH2 dysregulation in germinal center derived lymphomas, where she demonstrated that dual inhibition of EZH2 and HDAC is synergistic in EZH2 deregulated lymphomas. This data was accepted as an oral abstract at 2016 American Society of Hematology Annual Conference and was awarded an American Society of Hematology Abstract Achievement Award. As a direct result of the preliminary work performed on this project, Dr. Lue was awarded an ASCO Young Investigator’s Award in 2017 and will continue her research emphasizing the development of novel targeted therapies in lymphoma. Dr. Lue is also interested in pharmacokinetic and pharmacodynamics modeling, early clinical trial development, and biomarker development as a means to predict clinical response to therapy.

Additionally, Dr. Lue has published chapters and review articles on the biology and treatment of lymphoma. She is involved in numerous clinical trials for lymphoma, providing direct access to cutting edge therapies for our patients. Dr. Lue is a member of the American Society of Hematology and the American Society of Clinical Oncology and is dedicated to treatment of lymphoma as well as non-malignant disorders.